Biodesix (BDSX) Expected to Announce Quarterly Earnings on Monday

Biodesix (NASDAQ:BDSX) is expected to post its quarterly earnings results after the market closes on Monday, March 3rd. Analysts expect Biodesix to post earnings of ($0.07) per share and revenue of $19.92 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Biodesix Trading Down 2.5 %

Shares of NASDAQ:BDSX opened at $0.79 on Friday. The company has a market cap of $115.36 million, a P/E ratio of -2.03 and a beta of 1.06. The stock’s 50-day moving average is $1.14 and its 200-day moving average is $1.43. Biodesix has a 52-week low of $0.75 and a 52-week high of $2.04. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40.

Insider Activity

In other news, CEO Scott Hutton sold 83,660 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This trade represents a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 128,702 shares of company stock valued at $118,406. 69.20% of the stock is owned by insiders.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.